Category: Pharma, Life Sciences & Med Tech Players
-
Delhi High Court allows Dr. Reddy’s to enter Indian semaglutide market in March 2026, dismisses Novo Nordisk appeal
In a landmark judgment, the Delhi High Court has ruled that Novo Nordisk failed to prove why it should be granted an interim injunction against Dr. Reddy’s, but has ordered the latter not to proceed with sales in Indian until the patent-in-suit expires on March 20, 2026.
-
Federal Circuit tosses Pfizer’s $42M+8% verdict against Daiichi, AstraZeneca: claiming 81 combinations out of gazillions described defeats disclosure, enablement
In a precedential opinion, the central U.S. appeals court for patent rulings overturns a Texas jury verdict given the discrepancy between a broad description and a specific claim term.
-
Next UPC CoA landmark ruling: pragmatic on inventive-step standard; focused on when amendments could be presented; tough but fair on remedies (Edwards v. Meril)
Another major UPC appellate ruling came down on Tuesday, and it provides a variety of clarifications of transcendental importance.
-
UPC CoA reverses invalidation of Amgen patent, clarifies standards for added matter and sufficient disclosure; infringement action to resume
In a high-stakes life sciences case, the UPC’s CoA has provided its most far-reaching clarifications on (in)validity to date.
-
Boehringer wins PI against Dr. Reddy’s that blocks generic empagliflozin (Jardiance) sales in UK pending October 2026 trial: patent thickets work
In some jurisdictions it pays off for Boehringer Ingelheim to have created a patent thicket around empaglifozin (Jardiance) involving use and formulation patents.
-
PI spate: Novo Nordisk just obtained 29 injunctions (26 over patent, 3 over UCL) against semaglutide rivals in Germany, served at CPHI fair
Context: What’s new: Novo Nordisk has just obtained, served and enforced a whopping 29 preliminary injunctions (PIs) against (mostly Asian and to a lesser extent European) companies offering the active pharmaceutical ingredient semaglutide and/or pharmaceuticals containing semaglutide at the CPHI fair. The pan-European law firm of Hoyng Rokh Monegier, in collaboration with UK firm Bristows,…
-
Munich I Regional Court’s written reasons for multi-country pharma PI: out-of-district defendants can be sued, German procedures apply
The Munich I Regional Court’s headnotes are highly instructive and make the court an attractive forum for cross-border injunctions.
-
Pharma patent litigation updates: Boehringer, Orion, Pfizer, Kaleo file fresh patent infringement suits in District of Delaware
The District of Delaware continues to receive a substantial volume of pharmaceutical patent infringement complaints, with an arthritis-related Pfizer suit and diabetes-related Boehringer suit among the latest.
-
Munich I Regional Court’s stunning PI for 20+ countries: based on BSH, doctrine of equivalents, difficult-to-enforce formulation patent
Munich has been a patent injunction hotspot for many years, and the latest development may attract even more litigation to the venue.
-
AstraZeneca faces fresh mRNA patent infringement allegations in District of Delaware
Gene-editing tech company Factor Bioscience has sued AstraZeneca and its affiliate Cellectis over the infringement of three mRNA-related patents.